These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 388737)

  • 1. Topical prostacyclin (PGI2) inhibits platelet aggregation in pial venules of the mouse.
    Rosenblum WI; El-Sabban F
    Stroke; 1979; 10(4):399-401. PubMed ID: 388737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostacyclin (PGI2) inhibits the formation of platelet thrombi in arterioles and venules of the hamster cheek pouch.
    Higgs EA; Higgs GA; Moncada S; Vane JR
    Br J Pharmacol; 1978 Jul; 63(3):535-9. PubMed ID: 352466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of platelet aggregation with intravenous and oral administration of carboprostacyclin in man.
    Karim SM; Adaikan PG; Lau LC; Tai MY
    Prostaglandins Med; 1981 May; 6(5):521-7. PubMed ID: 7022510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intravenous infusion of prostacyclin (PGI2) in man.
    O'Grady J; Warrington S; Moti MJ; Bunting S; Flower R; Fowle AS; Higgs EA; Moncada S
    Prostaglandins; 1980 Feb; 19(2):319-32. PubMed ID: 6992228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostacyclin (PGI2) inhibits the formation of platelet thrombi in arterioles and venules of the hamster cheek pouch. 1977.
    Higgs EA; Higgs GA; Moncada S; Vane JR
    Br J Pharmacol; 1997 Feb; 120(4 Suppl):439-43; discussion 437-8. PubMed ID: 9142422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets.
    Wong PY; McGiff JC; Sun FF; Lee WH
    Eur J Pharmacol; 1979 Dec; 60(2-3):245-8. PubMed ID: 393526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction of sodium nitroprusside with human endothelial cells and platelets: nitroprusside and prostacyclin synergistically inhibit platelet function.
    Levin RI; Weksler BB; Jaffe EA
    Circulation; 1982 Dec; 66(6):1299-307. PubMed ID: 6291803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin delays platelet aggregation after injury of cerebral arterioles.
    Rosenblum WI; el-Sabban F; Hirsh PD
    Stroke; 1986; 17(6):1203-5. PubMed ID: 3810722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of combined parenchymal and vascular injury on platelet aggregation in pial arterioles of living mice: evidence for release of aggregate-inhibiting materials.
    Rosenblum WI; El-Sabban F
    Stroke; 1977; 8(6):691-3. PubMed ID: 929658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets.
    Hawiger J; Parkinson S; Timmons S
    Nature; 1980 Jan; 283(5743):195-7. PubMed ID: 6985716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man.
    Hassan S; Pickles H; Fish A; Burke C; Warrington S; O'Grady J
    Br J Clin Pharmacol; 1982 Sep; 14(3):369-77. PubMed ID: 6127095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation.
    Aiken JW; Gorman RR; Shebuski RJ
    Prostaglandins; 1979 Apr; 17(4):483-94. PubMed ID: 111306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-aggregatory effect of prostacyclin (PGI2) in vivo.
    Bayer BL; Blass KE; Förster W
    Br J Pharmacol; 1979 May; 66(1):10-2. PubMed ID: 378308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin neutralization of PGI2: effects upon platelets.
    Saba HI; Saba SR; Blackburn CA; Hartmann RC; Mason RG
    Science; 1979 Aug; 205(4405):499-501. PubMed ID: 377493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostacyclin (PGI2) in pregnant human uterus.
    Omini C; Folco GC; Pasargiklian R; Fano M; Berti F
    Prostaglandins; 1979 Jan; 17(1):113-20. PubMed ID: 220673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A scanning electron microscopic investigation of effects of prostacyclin on platelet retention in glass bead columns.
    Ts'ao C; Krajewski D; Ng A
    Scand J Haematol; 1982 Jan; 28(1):23-31. PubMed ID: 7041243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIa hypercholesterolemia.
    Colli S; Lombroso M; Maderna P; Tremoli E; Nicosia S
    Biochem Pharmacol; 1983 Jul; 32(13):1989-93. PubMed ID: 6347202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of platelet factor 3 availability by prostacyclin.
    Hársfalvi J; Muszbek L; Stadler I; Fésüs L
    Prostaglandins; 1980 Nov; 20(5):935-45. PubMed ID: 7008092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet and other effects of carboprostacyclin--a stable prostacyclin analogue.
    Adaikan PG; Karim SM; Lau LC
    Prostaglandins Med; 1980 Oct; 5(4):307-20. PubMed ID: 7003626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of prostacyclin (PGI2) on endotoxin shock and endotoxin-induced platelet aggregation in dogs.
    Fletcher JR; Ramwell PW
    Circ Shock; 1980; 7(3):299-308. PubMed ID: 7004660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.